Post-Marketing Surveillance of Humira Injection in Korean Patients Under the "New-Drug Re-examination"

Trial Profile

Post-Marketing Surveillance of Humira Injection in Korean Patients Under the "New-Drug Re-examination"

Completed
Phase of Trial: Phase IV

Latest Information Update: 19 Aug 2013

At a glance

  • Drugs Adalimumab (Primary)
  • Indications Ankylosing spondylitis; Crohn's disease; Plaque psoriasis; Psoriatic arthritis; Rheumatoid arthritis
  • Focus Adverse reactions
  • Sponsors Abbott Laboratories
  • Most Recent Events

    • 13 Aug 2012 Actual end date (1 Jun 2012)added as reported by ClinicalTrials.gov record.
    • 01 Jun 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 01 May 2012 Planned end date changed from 1 Jul 2012 to 1 May 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top